21 research outputs found
Alpha-Synuclein Pathology Coincides With Increased Number of Early Stage Neural Progenitors in the Adult Hippocampus
Alpha-synuclein pathology driven impairment in adult neurogenesis was proposed as
a potential cause of, or at least contributor to, memory impairment observed in both
patients and animal models of Parkinson’s disease (PD) and Dementia with Lewy
Bodies (DLB). Mice overexpressing wild-type alpha-synuclein under the Thy-1 promoter
(Thy1-aSyn, line 61) uniquely replicate early cognitive deficits together with multiple
other characteristic motor and non-motor symptoms, alpha-synuclein pathology and
dopamine loss. Here we report overt intracellular accumulation of phosphorylated alphasynuclein
in the hippocampus of these transgenic mice. To test whether this alters adult
neurogenesis and total number of mature neurons, we employed immunohistochemistry
and an unbiased stereology approach to quantify the distinct neural progenitor cells and
neurons in the hippocampal granule cell layer and subgranular zone of 6 (prodromal
stage) and 16-month (dopamine loss) old Thy1-aSyn mice. Surprisingly, we observed
an increase in the number of early stage, i.e., Pax6 expressing, progenitors whereas the
numbers of late stage, i.e., Tbr2 expressing, progenitors and neurons were not altered.
Astroglia marker was increased in the hippocampus of transgenic mice, but this was
not specific to the regions where adult neurogenesis takes place, arguing against a
commitment of additional early stage progenitors to the astroglia lineage. Together, this
uncovers a novel aspect of alpha-synuclein pathology in adult neurogenesis. Studying
its mechanisms in Thy1-aSyn mice could lead to discovery of effective therapeutic
interventions for cognitive dysfunction in PD and DLB
Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease
In Parkinson's disease (PD), the second most common neurodegenerative disorder, non-motor symptoms often precede the development of debilitating motor symptoms and present a severe impact on the quality of life. Lewy bodies containing misfolded α-synuclein progressively develop in neurons throughout the peripheral and central nervous system, which may be correlated with the early development of non-motor symptoms. Among those, increased fear and anxiety is frequent in PD and thought to result from pathology outside the dopaminergic system, which has been the focus of symptomatic treatment to alleviate motor symptoms. Alpha-synuclein accumulation has been reported in the amygdala of PD patients, a brain region critically involved in fear and anxiety. Here we asked whether α-synuclein overexpression alone is sufficient to induce an enhanced fear phenotype in vivo and which pathological mechanisms are involved. Transgenic mice expressing human wild-type α-synuclein (Thy1-aSyn), a well-established model of PD, were subjected to fear conditioning followed by extinction and then tested for extinction memory retention followed by histopathological analysis. Thy1-aSyn mice showed enhanced tone fear across acquisition and extinction compared to wild-type littermates, as well as a trend to less retention of fear extinction. Immunohistochemical analysis of the basolateral nucleus of the amygdala, a nucleus critically involved in tone fear learning, revealed extensive α-synuclein pathology, with accumulation, phosphorylation, and aggregation of α-synuclein in transgenic mice. This pathology was accompanied by microgliosis and parvalbumin neuron loss in this nucleus, which could explain the enhanced fear phenotype. Importantly, this non-motor phenotype was detected in the pre-clinical phase, prior to dopamine loss in Thy1-aSyn mice, thus replicating observations in patients. Results obtained in this study suggest a possible mechanism by which increased anxiety and maladaptive fear processing may occur in PD, opening a door for therapeutic options and further early biomarker research
Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson’s Disease
Aside from the classical motor symptoms, Parkinson’s disease also has various non-classical symptoms. Interestingly, orexin neurons, involved in the regulation of exploratory locomotion, spontaneous physical activity, and energy expenditure, are affected in Parkinson’s. In this study, we hypothesized that Parkinson’s-disease-associated pathology affects orexin neurons and therefore impairs functions they regulate. To test this, we used a transgenic animal model of Parkinson’s, the A53T mouse. We measured body composition, exploratory locomotion, spontaneous physical activity, and energy expenditure. Further, we assessed alpha-synuclein accumulation, inflammation, and astrogliosis. Finally, we hypothesized that chemogenetic inhibition of orexin neurons would ameliorate observed impairments in the A53T mice. We showed that aging in A53T mice was accompanied by reductions in fat mass and increases in exploratory locomotion, spontaneous physical activity, and energy expenditure. We detected the presence of alpha-synuclein accumulations in orexin neurons, increased astrogliosis, and microglial activation. Moreover, loss of inhibitory pre-synaptic terminals and a reduced number of orexin cells were observed in A53T mice. As hypothesized, this chemogenetic intervention mitigated the behavioral disturbances induced by Parkinson’s disease pathology. This study implicates the involvement of orexin in early Parkinson’s-disease-associated impairment of hypothalamic-regulated physiological functions and highlights the importance of orexin neurons in Parkinson’s disease symptomology
Alpha-Synuclein Pathology Coincides With Increased Number of Early Stage Neural Progenitors in the Adult Hippocampus
Alpha-synuclein pathology driven impairment in adult neurogenesis was proposed as
a potential cause of, or at least contributor to, memory impairment observed in both
patients and animal models of Parkinson’s disease (PD) and Dementia with Lewy
Bodies (DLB). Mice overexpressing wild-type alpha-synuclein under the Thy-1 promoter
(Thy1-aSyn, line 61) uniquely replicate early cognitive deficits together with multiple
other characteristic motor and non-motor symptoms, alpha-synuclein pathology and
dopamine loss. Here we report overt intracellular accumulation of phosphorylated alphasynuclein
in the hippocampus of these transgenic mice. To test whether this alters adult
neurogenesis and total number of mature neurons, we employed immunohistochemistry
and an unbiased stereology approach to quantify the distinct neural progenitor cells and
neurons in the hippocampal granule cell layer and subgranular zone of 6 (prodromal
stage) and 16-month (dopamine loss) old Thy1-aSyn mice. Surprisingly, we observed
an increase in the number of early stage, i.e., Pax6 expressing, progenitors whereas the
numbers of late stage, i.e., Tbr2 expressing, progenitors and neurons were not altered.
Astroglia marker was increased in the hippocampus of transgenic mice, but this was
not specific to the regions where adult neurogenesis takes place, arguing against a
commitment of additional early stage progenitors to the astroglia lineage. Together, this
uncovers a novel aspect of alpha-synuclein pathology in adult neurogenesis. Studying
its mechanisms in Thy1-aSyn mice could lead to discovery of effective therapeutic
interventions for cognitive dysfunction in PD and DLB
Alpha-Synuclein Pathology Coincides With Increased Number of Early Stage Neural Progenitors in the Adult Hippocampus
Alpha-synuclein pathology driven impairment in adult neurogenesis was proposed as
a potential cause of, or at least contributor to, memory impairment observed in both
patients and animal models of Parkinson’s disease (PD) and Dementia with Lewy
Bodies (DLB). Mice overexpressing wild-type alpha-synuclein under the Thy-1 promoter
(Thy1-aSyn, line 61) uniquely replicate early cognitive deficits together with multiple
other characteristic motor and non-motor symptoms, alpha-synuclein pathology and
dopamine loss. Here we report overt intracellular accumulation of phosphorylated alphasynuclein
in the hippocampus of these transgenic mice. To test whether this alters adult
neurogenesis and total number of mature neurons, we employed immunohistochemistry
and an unbiased stereology approach to quantify the distinct neural progenitor cells and
neurons in the hippocampal granule cell layer and subgranular zone of 6 (prodromal
stage) and 16-month (dopamine loss) old Thy1-aSyn mice. Surprisingly, we observed
an increase in the number of early stage, i.e., Pax6 expressing, progenitors whereas the
numbers of late stage, i.e., Tbr2 expressing, progenitors and neurons were not altered.
Astroglia marker was increased in the hippocampus of transgenic mice, but this was
not specific to the regions where adult neurogenesis takes place, arguing against a
commitment of additional early stage progenitors to the astroglia lineage. Together, this
uncovers a novel aspect of alpha-synuclein pathology in adult neurogenesis. Studying
its mechanisms in Thy1-aSyn mice could lead to discovery of effective therapeutic
interventions for cognitive dysfunction in PD and DLB
Oligodendrocyte-specific ATF4 inactivation does not influence the development of EAE
Abstract Background Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), are inflammatory demyelinating and neurodegenerative diseases of the CNS. Although recent studies suggest the neuroprotective effects of oligodendrocytes in neurodegenerative diseases, it remains unknown whether oligodendrocyte death induced by inflammatory attacks contributes to neurodegeneration in MS and EAE. Upon endoplasmic reticulum (ER) stress, activation of pancreatic ER kinase (PERK) promotes cell survival through induction of activating transcription factor 4 (ATF4) by phosphorylating eukaryotic translation initiation factor 2α (eIF2α). We have generated a mouse model that allows for temporally controlled activation of PERK specifically in oligodendrocytes. Our previous study has demonstrated that PERK activation specifically in oligodendrocytes attenuates EAE disease severity and ameliorates EAE-induced oligodendrocyte apoptosis, demyelination, and axon degeneration, without altering inflammation. Methods We determined whether oligodendrocyte-specific PERK activation reduced neuron loss in the CNS of EAE mice using the mouse model that allows for temporally controlled activation of PERK specifically in oligodendrocytes. We further generated a mouse model that allows for inactivation of ATF4 specifically in oligodendrocytes, and determined the effects of ATF4 inactivation in oligodendrocytes on mice undergoing EAE. Results We showed that protection of oligodendrocytes resulting from PERK activation led to attenuation of neuron loss in the CNS gray matter of EAE mice. Surprisingly, we found that ATF4 inactivation specifically in oligodendrocytes did not alter EAE disease severity and had no effect on oligodendrocyte loss, demyelination, axon degeneration, neuron loss, and inflammation in EAE mice. Conclusions These findings suggest the neuroprotective effects of PERK activation in oligodendrocytes in EAE, and rule out the involvement of ATF4 in oligodendrocytes in the development of EAE. These results imply that the protective effects of PERK activation in oligodendrocytes in MS and EAE are not mediated by ATF4